The interview was conducted by and published in European Business.
Biologics development is complex, capital-intensive and highly regulated. For biotech and pharmaceutical companies, choosing the right CDMO partner can determine how smoothly a molecule moves from early development into clinical and commercial manufacturing. Rezon Bio, operating from two sites in Poland, is positioning itself as a European biologics CDMO that combines regula¬tory experience, scientific expertise and cost-efficient execution. CEO Dr. Adriana Kiędzierska-Mencfeld explains how the company’s biosimilar heritage shapes its new role in the market
European Business: Dr. Kiędzierska-Mencfeld, Rezon Bio is a new brand. What is the story behind it?
Dr. Adriana Kiędzierska- Mencfeld: Rezon Bio was launched as a brand in September 2025, but the expertise behind it has been built over many years. We started as a biotechnology company developing our own biosimilar products. This gave us a very practical foundation, because we had to solve real development, manufacturing and regulatory challenges ourselves. Over time, we moved from early development to late-stage execution, global approvals and commercial supply. Opening this platform to external partners as a dedicated CDMO was therefore a natural next step.
European Business: What makes Rezon Bio different from other CDMOs?
Dr. Adriana Kiędzierska- Mencfeld: Our strongest differentiator is real product experience. We are not a CDMO built only around capacity. We have developed our own biosimilars, passed health authority inspections, including EMA and FDA inspections, and delivered commercial products to global markets. This gives us a deep understanding of what our clients are going through. Many companies today need more than manufacturing space. They need reliability, commercial readiness and a partner who understands both science and execution.
European Business: What services do you offer?
Dr. Adriana Kiędzierska- Mencfeld: We offer end-to-end development and manufacturing services for biologics, with a strong focus on mammalian production. Our experience includes monoclonal antibodies, biosimilars, enzymes and novel biologics. In Gdańsk, we cover early development, analytical method development, process development and clinical batches. Warsaw-Duchnice is our largest commercial-scale site, supporting scale-up, technology transfer, MSAT, lifecycle management, and process improvement. Today, more than 1,100 people work for Rezon Bio.
European Business: Who are your target customers?
Dr. Adriana Kiędzierska- Mencfeld: We mainly support biotech companies and small to mid-sized pharma companies developing biosimilars or novel biologics. At the same time, we continue to work with larger pharma companies, which is part of our legacy. Our ideal clients are companies that need more than capacity alone. We want to be a partner that plans properly, prioritizes carefully and supports clients with long-term potential.
European Business: How do you see the current market situation?
Dr. Adriana Kiędzierska-Mencfeld: The market is under strong cost pressure, while quality expectations remain very high. This is challenging, but it also creates opportunities. At Rezon Bio, we offer European quality and regulatory standards with a cost-competitive approach. We are not competing purely on Asian price levels, but we can provide a strong European alternative with high quality, reliability and lower geopolitical risk.
European Business: What are your priorities for the coming years?
Dr. Adriana Kiędzierska-Mencfeld: Our priority is to strengthen our CDMO business while preserving what defines us: quality, reliability, scientific depth and client focus. We want to help clients move smoothly from development into clinical and commercial manufacturing. Continuous improvement is also essential, especially in how we use data, optimize processes and improve cost efficiency.
European Business: Which values guide the company?
Dr. Adriana Kiędzierska-Mencfeld: Our culture is built around integrity, dedication, ownership, cost consciousness and passion. Integrity is fundamental because our clients need trust and transparency. Ownership means that our teams feel responsible for outcomes, not only activities. Cost consciousness reflects market reality, and passion is essential because biologics manufacturing is highly demanding. Excellence comes from people who genuinely care about solving problems and delivering results.
European Business: What role do digitalization and sustainability play?
Dr. Adriana Kiędzierska-Mencfeld: Both are important, but we approach them pragmatically. Digitalization should improve process understanding, operational visibility, decision-making, and efficiency. Sustainability is also closely connected to operational excellence. For us, ESG is not a separate topic; it is linked to quality, compliance, reliability, and responsible business practice.
